J.P. Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer
MedCity News
APRIL 30, 2024
With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies. Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer appeared first on MedCity News. The post J.P.
Let's personalize your content